FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Nexlizet (bempedoic acid and ezetimibe) submitted by Esperion Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• NEXLIZET (bempedoic acid and ezetimibe)

Snippet

SUPPL AP for NEXLIZET (BEMPEDOIC ACID AND EZETIMIBE)